The Role of Osteopontin in Cancer Progression and Bone Metastasis
骨桥蛋白在癌症进展和骨转移中的作用
基本信息
- 批准号:7276197
- 负责人:
- 金额:$ 3.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-06-01 至 2009-05-31
- 项目状态:已结题
- 来源:
- 关键词:1-Phosphatidylinositol 3-KinaseAntibodiesApoptosisBindingBiochemical PathwayBiological AssayBiological ModelsBreastCD44 geneCancer ModelCell AdhesionCell LineCell Surface ReceptorsCell SurvivalCell physiologyCellsClinical MedicineCo-ImmunoprecipitationsDevelopmentDominant-Negative MutationEventExtracellular Matrix ProteinsHumanIn VitroIntegrin BindingIntegrinsInvestigationKnowledgeMalignant NeoplasmsMalignant neoplasm of pancreasMalignant neoplasm of prostateMandibleMeasuresMediatingMediator of activation proteinMetastatic Neoplasm to the BoneMolecularNeoplasm MetastasisPathway interactionsPhosphoinositide-3-Kinase, Catalytic, Gamma PolypeptidePhosphorylationPhosphorylation SitePhosphotransferasesPlayProcessProstateProtein OverexpressionRGD (sequence)Receptor CellRegulationRoleSignal PathwaySignal TransductionStreamStructureSystemTestingadhesion receptorcancer cellinhibiting antibodyinhibitor/antagonistintegrin-linked kinaseinterestmigrationmutantosteopontinprognosticreceptorreceptor functionresearch studyresponserho GTP-Binding Proteinstherapeutic targettumor growthtumor progression
项目摘要
DESCRIPTION (provided by applicant): The long-term objective of this project is to elucidate the signaling pathways stimulated by osteopontin (OPN) which increase cell survival while also stimulating cancer cell metastasis. Osteopontin interaction with adhesion receptors such as integrins and CD44 mediates many cellular processes, including cell adhesion, migration, proliferation, and survival. The role of OPN in cancer progression is of increasing interest as recent studies have noted that OPN is overexpressed in breast, prostate, and pancreatic cancers; OPN may also be a potential prognostic indicator of metastasis. A key step in elucidating the role of OPN in cancer came when it was shown to increase the activation of PKB/Akt, an important molecule for regulating cell survival and progression. Constitutive activation of Akt is frequently observed in many types of human cancers, the causative role of this kinase as well as the signaling pathway(s) involved in their survival and progression is unknown. This proposal aims to more fully decipher the role of OPN in cancer cell survival and metastasis by first elucidating the roles of the integrin aVp3 and the cell surface receptor CD44 in the regulation of cancer cell survival and progression through Akt. Specific cell receptor inhibitors including SiRNA, and inhibiting antibodies will be used to determine the molecular interactions involved in the initiation of OPN mediated Akt activation. Prostate cancer cells (PCS) have been chosen as a model system due to there ability to express OPN and metastasize to osseous structures, including the mandible. The down stream effects of the engagement of OPN and its cell surface receptors will focus on the cell signaling changes of integrin linked kinase (ILK) and PI3-kinase, two important regulators in the Akt cell survival mechanism. OPN mediated Akt cell survival and metastasis will be further elucidated via using specific molecular inhibitors to ILK and PI3-K while also investigating the role of OPN on their kinase activity. This proposal aims to elucidate metastatic and survival mechanisms by testing the over all hypothesis that the synergistic activity of OPN on its cellular receptors elicits the down stream cell signaling changes via activating the PI3-kinase/Akt and ILK/Akt pathways which play a crucial role in the survival, migration, tumor growth, and metastatic events of cancer cells. Osteopontin is an extracellular matrix protein which has been implicated in the progression of cancer as an important mediator of cell adhesion, migration, proliferation, and survival. Further investigation into the role of osteopontin in cancer may open new doors in clinical medicine by increasing the knowledge of the mechanisms involved in cancer progression and thus providing additional therapeutic targets.
描述(由申请人提供):该项目的长期目标是阐明骨桥蛋白(OPN)刺激的信号通路,该信号通路增加细胞存活,同时刺激癌细胞转移。骨桥蛋白与粘附受体如整合素和CD 44的相互作用介导许多细胞过程,包括细胞粘附、迁移、增殖和存活。OPN在癌症进展中的作用越来越受到关注,因为最近的研究已经注意到OPN在乳腺癌、前列腺癌和胰腺癌中过表达; OPN也可能是转移的潜在预后指标。阐明OPN在癌症中的作用的关键一步是当它被证明增加PKB/Akt的激活时,PKB/Akt是调节细胞存活和进展的重要分子。Akt的组成性激活经常在许多类型的人类癌症中观察到,这种激酶的致病作用以及参与其存活和进展的信号传导途径尚不清楚。该提案旨在通过首先阐明整合素aVp 3和细胞表面受体CD 44在通过Akt调节癌细胞存活和进展中的作用,更全面地解读OPN在癌细胞存活和转移中的作用。将使用特异性细胞受体抑制剂(包括SiRNA)和抑制抗体来确定参与OPN介导的Akt激活启动的分子相互作用。前列腺癌细胞(PCS)已被选为模型系统,因为有能力表达OPN和转移到骨结构,包括下颌骨。OPN与其细胞表面受体相互作用的下游效应将集中在Akt细胞生存机制中两个重要调节因子--整合素连接激酶(integrin linked kinase,ILK)和磷脂酰肌醇3-激酶(PI 3-kinase)的细胞信号变化上。OPN介导的Akt细胞存活和转移将通过使用ILK和PI 3-K的特异性分子抑制剂进一步阐明,同时还研究OPN对其激酶活性的作用。该提案旨在通过测试OPN对其细胞受体的协同活性通过激活PI 3-激酶/Akt和ILK/Akt通路来激发下游细胞信号传导变化的总体假设来阐明转移和存活机制,所述PI 3-激酶/Akt和ILK/Akt通路在癌细胞的存活、迁移、肿瘤生长和转移事件中起关键作用。骨桥蛋白是一种细胞外基质蛋白,作为细胞粘附、迁移、增殖和存活的重要介质,与癌症的进展有关。进一步研究骨桥蛋白在癌症中的作用可能会为临床医学打开新的大门,增加对癌症进展机制的了解,从而提供额外的治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brian Wilson Robertson其他文献
Brian Wilson Robertson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brian Wilson Robertson', 18)}}的其他基金
The Role of Osteopontin in Cancer Progression and Bone Metastasis
骨桥蛋白在癌症进展和骨转移中的作用
- 批准号:
7433289 - 财政年份:2007
- 资助金额:
$ 3.28万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 3.28万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 3.28万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 3.28万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 3.28万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 3.28万 - 项目类别: